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Objective: Investigate a role for calcitonin gene-related peptide (CGRP) in osteoarthritis (OA)-related
pain.
Design: Neutralizing antibodies to CGRP were generated de novo. One of these antibodies, LY2951742,
was characterized in vitro and tested in pre-clinical in vivo models of OA pain.
Results: LY2951742 exhibited high afﬁnity to both human and rat CGRP (KD of 31 and 246 pM, respec-
tively). The antibody neutralized CGRP-mediated induction of cAMP in SK-N-MC cells in vitro and
capsaicin-induced dermal blood ﬂow in the rat. Neutralization of CGRP signiﬁcantly reduced pain
behavior as measured by weight bearing differential in the rat monoiodoacetate model of OA pain in a
dose-dependent manner. Moreover, pain reduction with neutralization of CGRP occurred independently
of prostaglandins, since LY2951742 and NSAIDs worked additively in the NSAID-responsive version of the
model and CGRP neutralization remained effective in the NSAID non-responsive version of the model.
Neutralization of CGRP also provided dose-dependent and prolonged (>60 days) pain reduction in the
rat meniscal tear model of OA after only a single injection of LY2951742.
Conclusions: LY2951742 is a high afﬁnity, neutralizing antibody to CGRP. Neutralization of CGRP is efﬁ-
cacious in several OA pain models and works independently of NSAID mechanisms of action. LY2951742
holds promise for the treatment of pain in OA patients.
 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The most common form of arthritis is osteoarthritis (OA). A
variety of factors can lead to the development of OA, all resulting in
a reduction in the mobility and normal functioning of the joint1. Ino: R.J. Benschop, Eli Lilly &
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ternational. Published by Elsevier Laddition to loss of function, joint pain is a major factor in reducing
the quality of life for patients with OA. The exact source of pain
related to OA is poorly understood though several parts of the joint,
including subchondral bone, periosteum, synovium, and the joint
capsule, are highly innervated and could thus be the origin of
nociceptive stimuli2e4.
Calcitonin gene-related peptide (CGRP) is a 37 amino acid
peptide that is widely expressed in the central and peripheral
nervous system5. It is primarily associatedwith small unmyelinated
sensory neurons, which are in close proximity of blood vessels.
CGRP is a potent vasodilator and local administration of CGRP
causes transient increases in blood ﬂow6,7. CGRP has also been
associated with pain transmission, pain modulation, and neuro-
genic inﬂammation8. CGRP can be released from sensory neurons
via activation of the transient receptor potential cation channel V1
(TRPV1) using capsaicin9. Laser Doppler Imaging (LDI) has been
used to detect the resulting changes in dermal blood ﬂow and this
has been shown to be predominantly caused by CGRP10. CGRP istd. All rights reserved.
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responses in CGRP knock-out mice in a number of pain models11,12.
This role in pain perception is congruent with the expression of
CGRP in sensory neurons.
OA pain can be modeled pre-clinically in rats injected intra-
articularly with monoiodoacetate (MIA). Injection of MIA into the
knee joint produces an acute inﬂammatory insult and inhibits
chondrocyte metabolism which then develops into chronic
degeneration of tissues in the injected joint13,14. Similarly OA pain
can also be modeled in a less inﬂammatory surgical model, the rat
meniscal tear (MT) model15. In this model of OA, joint destruction
and pain occur after surgical destabilization of the knee joint by
transection of the medial collateral ligament and medial meniscus.
The pain resulting from the joint injury in both models can be
measured via differential weight bearing of the hind legs using an
incapacitance tester. Efﬁcacy for treating pain in both models has
been described for standards of care for OA such as the nonsteroidal
anti-inﬂammatory drugs (NSAIDs) diclofenac, naproxen, and cele-
coxib, as well as opiates such as morphine13,15,16. Similar to human
OA, both models have also been shown to become non-responsive
to NSAIDs with increasing time after induction (authors’ unpub-
lished data for MT model and17).
We hypothesized that CGRP could play a role in OA pain due to
dense innervation with CGRP-positive neurons in the joint2e4 and
the link between CGRP and inﬂammatory pain11,12. We describe the
generation of a highly speciﬁc and potent humanized antibody to
CGRP, LY2951742. The antibody binds and neutralizes both human
and rat CGRP in vitro. In addition, it prevents capsaicin-induced
dermal vasodilatation in vivo, a phenomenon known to depend
on the release of endogenous CGRP from sensory neurons.
Neutralization of CGRP is efﬁcacious in a number of pre-clinical
models of OA pain, providing prolonged pain relief with only a
single injection of the antibody. Pain involving CGRP is independent
of prostaglandins, as shown by additive effects of CGRP neutrali-
zation and prostaglandins in the MIA model, and by efﬁcacy with
CGRP neutralization in a NSAIDs non-responsive model. Our ﬁnd-
ings demonstrate a role for CGRP in OA-related pain and suggest
potential therapeutic approaches to treat this pain in patients.
Method
Generation of antibodies to CGRP
In order to generate antibodies speciﬁc to human CGRP, BALB/c
mice were immunized with human CGRP conjugated to ovalbumin.
Antibodies were screened for the ability to bind human CGRP and
several were selected and subsequently humanized, optimized for
afﬁnity and developability, and expressed as human IgG418. Here
we describe the characteristics of one of these molecules,
LY2951742.
Binding afﬁnity and speciﬁcity
Binding afﬁnity and stoichiometry was determined using a
surface plasmon resonance (SPR) assay on a Biacore T100 instru-
ment primed with HBS-EPþ (GE Healthcare, 10 mM HEPES pH
7.4 þ 150 mM NaCl þ 3 mM EDTA þ 0.05% surfactant P20) running
buffer and analysis temperature at 37C. A CM5 chip containing
immobilized protein A was used to capture LY2951742. Brieﬂy,
antibody samples were prepared at 2 mg/mL and human or rat CGRP
(Bachem)were prepared at 5.0, 2.5,1.3, 0.63, 0.31, and 0 (blank) nM.
Data were processed using standard double-referencing and ﬁt to a
1:1 binding model to determine the association rate (kon, M1 s1
units), dissociation rate (koff, s1 units), and Rmax (RU units). The
equilibrium dissociation constant (KD) was calculated from therelationship KD ¼ koff/kon. Tests for binding to human adrenome-
dullin, intermedin, amylin, and calcitonin (Bachem) at concentra-
tions up to 500 nM were performed using this same basic
procedure. For some peptides that exhibited higher levels of non-
speciﬁc binding to the chip, binding was tested in buffer contain-
ing higher levels of NaCl (500 mM) to reduce non-speciﬁc binding.
In vitro activity assay
The human neuroepithelioma cell line SK-N-MC naturally ex-
presses the CGRP receptor and was used to assess whether
LY2951742 was able to inhibit CGRP-induced cAMP production. SK-
N-MC cells were cultured in MEM, containing 10% FBS, 1X MEM
non-essential amino acids, 1  100 mM MEM sodium pyruvate, 1X
Pen/Strep, and 2 mM L-glutamine. After harvesting, cells were
washed once and resuspended in assay buffer (stimulation buffer
(HBSS with Mg and Ca, 5 mM HEPES, 0.1% BSA, 100 mM ascorbic
acid) diluted 1:2 with Dulbecco’s PBS containing a ﬁnal concen-
tration of 0.5 mM IBMX) and plated in 96-well plates at 15,000 cells
per well. LY2951742 or a control human IgG4 antibody were added
(serial 4-fold dilutions in assay buffer, 10 concentrations) to the
cells, followed by a ﬁxed amount of human or rat CGRP (2 nM).
Plates were incubated for 1 h at room temperature. Levels of cAMP
were subsequently measured by a homogeneous time resolved
ﬂuorescence assay system (Cisbio). The percentage inhibition was
calculated relative to the amount of cAMP induced by 2 nM human
or rat CGRP in assay buffer alone.
In vivo studies
All animal studies conformed to protocols approved by the Eli
Lilly Institutional Animal Care and Use Committee. In all studies,
operators were blinded to the treatments and all antibodies were
prepared in PBS.
Laser Doppler Imaging
Male Lewis Rats (n ¼ 8/group) were dosed subcutaneously (sc)
with either 4 mg/kg of LY2951742 or an isotype control antibody 5
days prior to capsaicin challenge. Rats were fasted overnight prior
to capsaicin challenge. On the day of the experiment, the rat ab-
domens were shaved and the rats were placed in a heated air
chamber on a heating pad under the LDI instrument. A rectal probe
was used throughout the study for temperature monitoring.
Anesthesia was induced with 5% isoﬂurane in 1.5 L/min O2 and the
rat was stabilized under 2.5% isoﬂurane anesthesia for approxi-
mately 20 min prior to scanning. The scan series began with two
baseline scans after which 8 ml of capsaicin solution (50 mg
capsaicin in a solution of 60 ml EtOH, 40 ml Tween 20 and 100 ml
puriﬁed H2O) was applied to each of three o-rings placed on the
abdomen. Scanning continued with a scan every 2.5 min for an
additional 25 min. Data were analyzed using Moor v.5.2 software
for region of interest analysis and Microsoft Excel worksheets were
used for averaging the signal from the regions of interest at each
time point. Data are reported as percent change from baseline (the
average of two baseline scans).
MIA model
For all studies,w8-week old male Lewis rats (n¼ 6/group) were
used in two different versions of the MIA model. For MIA injection,
rats were anesthetized using 5% isoﬂurane in 1.5 L/min O2. In the
standard version, the right knee of each rat was injected with
0.3mgMIA in 50 ml of saline and the left kneewith 50 ml of saline. In
our experience, this dose (0.3 mg MIA) provides a consistent pain-
Table I
LY2951742 Binding Kinetics and Afﬁnity to human and rat CGRP. Surface Plasmon
resonance was used to determine the association (Kon) and dissociation (Koff) rates,
from which the afﬁnity (KD) was calculated (Koff/Kon). Mean (95% CI) of 5e6
experiments is shown
Antigen kon M1 s1 (106) koff s1 (104) KD pM N
Human CGRP 7.4 (6.1; 8.7) 2.2 (0.9; 3.6) 31 (11; 51) 6
Rat CGRP 8.2 (4.5; 12.0) 19 (15; 23) 246 (167; 325) 5
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resistant. An NSAID non-responsive form of the MIA model was
induced by injecting 1 mg of MIA in the right knee. Pain-related
behavior was measured using incapacitance testing, measuring
the difference in hind paw weight bearing between the MIA and
saline injected knees13. For each rat, the measurement reported in
these studies was the average of three separate 1-s measurements.
In all studies rats were randomized by weight into treatment
groups. Previous experience coupled with statistical analysis has
shown that the induced pain behavior varies very little between
animals and baseline pain measurements are not needed for
randomization. This is also true for the meniscal tear model (see
below).
Standard MIA model
Dose response with LY2951742 e 14 days post 0.3 mg MIA in-
jection, rats were dosed sc with LY2951742 (1, 4, or 16 mg/kg) or
isotype control antibody (16 mg/kg) at a dose volume of 2 ml/kg.
Pain-related behavior was measured 3 days post-dose with animals
from each dose group measured randomly throughout the day of
measurement.
Combination study with LY2951742 and NSAID diclofenac e 15
days post 0.3 mg MIA injection, rats were dosed sc with either
LY2951742 or isotype control antibody (1 mg/kg) at a dose volume
of 1 ml/kg (n ¼ 6 per group with two groups for each treatment).
Three days post-dose, LY2951742 or isotype control groups were
given either diclofenac (dosed orally with 0.1 mg/kg) or vehicle
(0.9% saline; dose volume 5 ml/kg). Pain-related behavior was
measured 2 h post-dose for each rat.
NSAID non-responding MIA model
Forty days post MIA injection (1 mg) rats were dosed sc with
either LY2951742 or isotype control antibody (4 mg/kg) at a dose
volume of 1 ml/kg. Three days later animals dosed with either
isotype control antibody or LY2951742 were dosed orally with
vehicle (saline) and a further group of MIA animals were dosed
with 5 mg/kg diclofenac. Dose volume was 5 ml/kg. Pain-related
behavior was measured 2 h post-dose for each rat.
Meniscal tear (MT) model
This is awell describedmodel of OAwhere joint destruction and
pain occur after surgical destabilization of the right knee joint by
transection of the medial collateral ligament and medial meniscus.
The left knee does not undergo surgery19. Male Lewis rats between
15 and 16 weeks of age underwent MT surgery (day 0) and 16 days
post-surgery, animals were randomized by weight and dosed sc
with LY2951742 (0.25, 1, or 4 mg/kg) or an isotype control (4 mg/
kg), at a dose volume of 1 ml/kg (n ¼ 6/group). Pain-related
behavior was determined using incapacitance testing on days 3, 7,
14, 18, 25, 32, 39, 46, and 60 post dosing. Animals were measured
randomly throughout the day of measurement.
In vivo exposure
To conﬁrm exposure, antibody levels in plasma were analyzed
using ELISA. Plates were coated overnight (4C) with goat anti-
human IgG (Fc speciﬁc; Jackson ImmunoResearch) in carbonate
coating buffer (pH 9.6), washed three times with wash buffer
(0.02M Tris pH 7.4, 0.15MNaCl, 0.1% Tween-20) and blocked for 1 h
at room temperature with 1% BSA in wash buffer. Plasma samples
were tested in duplicate at several dilutions. Captured antibodywas
detected using a donkey anti-human (H þ L)-HRP (JacksonImmunoResearch), the assay was developed using o-phenyl-
enediamene (SigmaeAldrich), and the reaction was stopped by
adding 1 N HCl. A standard curve of puriﬁed antibody was used to
calculate the plasma concentration.
Statistical evaluations
For the LDI studies, results were analyzed using a repeated
measurementmixed-effect model in SAS 9.1 (SAS Institute Inc., NC).
In the MIA studies data were evaluated by ANOVA. Groups were
compared to vehicle by Dunnett’s test while the Tukey Kramer HSD
test was utilized for pair comparison, using JMP (version 6) statis-
tical analysis software. Differences were considered to be signiﬁ-
cant if the P value was less than 0.05. For the MT data, a repeated
measure analysis was used (P < 0.05 for signiﬁcance). The tests at
each time point were done at a signiﬁcance level of 0.0167 to adjust
for multiplicity.
Results
LY2951742 speciﬁcally binds CGRP with high afﬁnity
Binding characteristics of LY2951742 to human and rat CGRP
were determined by SPR under physiological buffer conditions
(ionic strength and pH) and temperature (37C). Data in Table I
shows that LY2951742 binds to human CGRP with an association
rate (kon) of 7.4  106 M1 s1 and a dissociation rate (koff) of
2.2  104 s1, resulting in a 31 pM binding afﬁnity. Likewise,
LY2951742 binds to rat CGRP with kon ¼ 8.2  106 M1 s1 and
koff ¼ 1.9  103 s1, resulting in a binding afﬁnity of 246 pM. Thus,
the difference in species afﬁnity is driven primary by a faster
dissociation rate for rat CGRP. Nevertheless, LY2951742 binds both
human and rat CGRP with relatively high (sub-nanomolar) afﬁnity.
The binding speciﬁcity of LY2951742 was determined by inves-
tigating its binding to other peptides of the calcitonin family.
Binding to human adrenomedullin, intermedin, amylin, and calci-
tonin were performed at concentrations up to 500 nM (>10,000
fold higher than the KD of LY2951742 to human CGRP) using the
same SPR assay. Of these, adrenomedullin bound non-speciﬁcally
to the surface of the chip [Fig. 1(A)], whereas the binding proﬁle
to the surface of calcitonin and intermedin was comparable to that
observed for amylin (data not shown). LY2951742 displayed no
signiﬁcant speciﬁc binding to any of the peptides tested [Fig. 1(B)];
the low level of binding to adrenomedullin was only observed at
high (100) peptide concentrations and is probably related to the
non-speciﬁc binding observed to the chip surface [Fig. 1(A)]. These
results demonstrate high speciﬁcity of LY2951742 for CGRP.
LY2951742 neutralizes CGRP-induced receptor activation in vitro
The CGRP receptor is a hetero-trimeric complex consisting of the
Calcitonin receptor-Like Receptor (CLR, a G-protein coupled re-
ceptor) and Receptor Activity Modifying Protein (RAMP)-1, coupled
cytoplasmically to Receptor Component Protein (RCP)5. The binding
Fig. 1. Binding characteristics of LY2951742 to peptides of the calcitonin family. Surface Plasmon Resonance was used to determine binding of different concentrations of CGRP
(0.56, 1.7, or 5 nM), or adrenomedullin, amylin, intermedin, and calcitonin (all at 56, 167, or 500 nM) to either a control surface (A) or a surface coated with LY2951742 (B). Graphs
show binding (expressed as an increase in relative units) over time (seconds).
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tion. The human neuroepithelioma cell line SK-N-MC expresses the
CGRP receptor complex naturally and was used to assess the effect
of CGRP on signal transduction events. LY2951742 inhibited human
or rat CGRP-induced cAMP production in a concentration-
dependent manner, with 100% inhibition at the highest
LY2951742 concentrations (Fig. 2). On average, the IC50 was 0.35 nM
(95% CI: 0.24e0.46, n ¼ 4). In contrast, no inhibition of CGRP-
induced cAMP was observed with an isotype control antibody. In
accordance with a lower afﬁnity for rat compared to human CGRP,
the average IC50 value for rat CGRP was 1.05 nM. This demonstrates
that LY2951742 is a functional antagonist of both human and rat
CGRP, effectively preventing CGRP from binding and activating its
receptor.Fig. 2. LY2951742 inhibition of CGRP-induced cAMP response in SK-N-MC cells. cAMP
formation was induced by either human (ﬁlled squares) or rat (ﬁlled triangles) CGRP;
this was inhibited in a concentration-dependent manner by LY2951742, with isotype
control showing no inhibition (open diamonds). Mean  SEM of two independent
experiments is shown.LY2951742 prevents capsaicin-induced dermal blood ﬂow
Capsaicin-induced dermal vasodilatation was used as a direct
pharmacodynamic measure of CGRP activity to determine whether
LY2951742 was able to prevent CGRP-mediated dermal vasodila-
tation in rat abdominal skin. Previous studies with other anti-CGRP
antibodies administered sc as a single dose (4 mg/kg) 3 days before
the dermal blood ﬂow imaging experiment showed a clear pre-
ventative effect (data not shown). LY2951742, or an isotype control
antibody, was administered subcutaneously as a single dose (4 mg/
kg) 5 days before the dermal blood ﬂow imaging experiment. Theaverage serum level of LY2951742 on day 5 was 21.3 mg/ml (95% CI:
18.0e24.5, n ¼ 8). Capsaicin induced an approximate 150% increase
in dermal blood ﬂow in control animals within the observation
period (Fig. 3). In contrast, LY2951742-treated animals had a
Fig. 3. LY2951742 inhibits capsaicin-induced dermal blood ﬂow in vivo. A single dose
of LY2951742 or isotype control (4 mg/kg) was given sc 5 days prior to capsaicin
challenge. Changes in vasodilatation in the skin were monitored by LDI. The blood ﬂow
change is displayed as % change from baseline over time (n ¼ 8/group, mean  95% CI;
Repeated Measures ANOVA, **P < 0.001).
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blood ﬂow. These results demonstrate that LY2951742 effectively
neutralizes CGRP-induced biological effects in vivo.
LY2951742 reduces pain-related behavior in the rat MIA model
In a doseeresponse study, all three doses of LY2951742 (1, 4, or
16 mg/kg) tested signiﬁcantly reduced OA-related knee pain in
animals that had been injected with 0.3 mg MIA 17 days prior to a
single sc administration of LY2951742 (see Fig. 4(A)). The 4 mg/kg
dose was also signiﬁcantly more efﬁcacious than the 1 mg/kg dose
[Fig. 4(A)].
As described previously, NSAIDs such as diclofenac are stan-
dards of care for many OA patients and show efﬁcacy in the MIA
model (our unpublished data and13,16). Since NSAIDs and
LY2951742 most likely work on different pain pathways, there is
the potential for LY2951742 to be administered to patients
already on NSAID treatment. Therefore, we investigated whether
a combination treatment of the NSAID diclofenac with LY2951742
would provide more pain relief than either treatment alone. The
results shown in Fig. 4(B) demonstrate that both LY2951742 and
diclofenac alone signiﬁcantly reduced pain-related behavior vs
vehicle-dosed isotype control rats (34% and 25% respectively;
Fig. 4(B)). In addition, the combination of LY2951742 andFig. 4. Effect of CGRP neutralization with LY2951742 in the MIA model. A) Dose response st
behavior for either a single dose of LY2951742 (1 mg/kg) or a single dose of diclofenac (0.1 m
responding MIA model on pain-related behavior. All data are presented as mean  95% CI
niﬁcant), followed by Tukey Kramer HSD test for comparison between groups (*P < 0.05).diclofenac provided superior pain relief (45%) compared to either
LY2951742 or diclofenac alone [Fig. 4(B)]. These results suggest
that CGRP and prostaglandins play independent roles in the MIA
model.
As OA progresses, some patients reportedly become less
responsive or, in some cases, non-responsive to treatment with
NSAIDs. The underlying mechanism is unclear but may be the
result of changes in pain pathways (e.g., from inﬂammatory to
neuropathic) as the disease progresses. This has been modeled
pre-clinically in the MIA model by injecting a higher dose of MIA
(1.0 mg) and leaving the animals for greater than 35 days post MIA
injection before treatment is started. Under these conditions,
doses of NSAID that would typically reduce pain-related behavior
become ineffective (17 and unpublished data). It was demonstrated
in this version of the MIA model that LY2951742 signiﬁcantly
inhibited pain-related behavior vs isotype control whereas the
NSAID diclofenac had no effect on pain-related behavior [Fig. 4(C)].
This suggests that CGRP may play an important role in OA pain
when the disease progresses to a state where NSAIDs are no
longer effective.LY2951742 diminishes pain-related behavior in rat MT model
To conﬁrm the efﬁcacy for treating OA pain seen in the MIA
model, we determined whether CGRP also plays a role in pain in
the MT model of OA pain, by measuring pain-related behavior
over time following a single injection with LY2951742 (0.25, 1, or
4 mg/kg). There was a dose- and time-dependent effect of
LY2951742 on pain-related behavior [Fig. 5(A)]. Remarkably, for
both the 1 and 4 mg/kg doses of LY2951742 only a single injection
resulted in signiﬁcant efﬁcacy that was maintained out to at least
60 days. By comparison, the 0.25 mg/kg dose of LY2951742 had a
lesser effect but did show signiﬁcant efﬁcacy for 25 days. Inter-
estingly, the observed efﬁcacy goes beyond what would have
been predicted based on plasma concentration [Fig. 5(B)]. It was
noted that during the ﬁrst week following dosing, the isotype
control group had a lower level of pain-related behavior than the
0.25 and 1 mg/kg groups, but this increased and stabilized at
about 14 days post injection and remained stable for the duration
of the experiment. There is no immediate explanation for this
observation; based on our previous experience with this model, a
weight differential of 46e50 g is consistently seen in non-treated
MT rats and this is why a baseline was not taken before dosing
and animals were randomized based on body weight. These re-
sults demonstrate a role for CGRP in pain in the MT model and
that neutralization with LY2951742 with a single dose provides
prolonged pain relief.udy with LY2951742 on pain-related behavior. B) Comparing reduction in pain-related
g/kg) vs both molecules dosed in combination. C) Effect of LY2951742 in the NSAID non-
with n ¼ 6/group. Statistical comparisons: Dunnett’s test (**P < 0.001; ns ¼ not sig-
Fig. 5. A) Effect of CGRP neutralization with LY2951742 in the MT model on pain-
related behavior. Statistical comparisons were performed comparing individual
doses vs isotype control (dashed line) over all time points using a repeated measure
analysis (**P < 0.001). B) Quantitation of plasma LY2951742 levels (mg/ml) over time in
the MT model. All data are presented as mean  95% CI with n ¼ 6/group.
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Here we describe a novel neutralizing antibody to CGRP,
LY2951742, and suggest that it may be used to alleviate pain in OA.
The demonstrated speciﬁcity for CGRP and neutralization in rele-
vant in vitro and in vivo experiments provide validation for this
antibody. Furthermore, our results in pre-clinical rat models of OA
demonstrate that CGRP plays an important role in OA-related pain.
This notion is supported by a number of studies demonstrating that
sensory innervations are associated with nociception in human OA:
the up-regulation of CGRP- and Substance P-positive neurons in the
joints of OA patients suggests that neuropeptides are involved in
the maintenance of this painful degenerative joint disease from the
periphery20e22. Speciﬁcally, a role for CGRP in pain was suggested
by the observation that an increase in CGRP-positive ﬁbers was only
seen in OA hip joints from patients experiencing pain and not in
non-painful joints20. Taken together, these data suggest a critical
role for CGRP in OA-associated pain.
The CGRP pathway has been clinically validated in pain associ-
ated with migraine using antagonists of the CGRP receptor23,24. In
these studies, CGRP antagonists administered during a migraine
attack effectively reduced the pain and associated symptoms. Our
data demonstrate that an antibody to CGRP can also be used to
effectively inhibit the CGRP pathway in vivo. The binding kinetics of
LY2951742, with its fast association rate presumably allows it to
bind CGRP before it can bind to the receptor, while the slow
dissociation rate ensures that CGRP will not be released. The rela-
tively long half-life of an antibody allows for a long duration of
effect with only a single dose. The current data demonstrate this inthe dermal blood ﬂow model using LDI where a single dose was
efﬁcacious for up to 5 days (the longest period tested) and is in line
with a previous report where electrically-induced vasodilatation
was inhibited with a neutralizing antibody to CGRP for up to 7
days25. The very long duration of effect in the MTmodel (>60 days)
even suggests there is a longer time action than the circulation half-
life would have suggested. In the rat MIA model, an increase in
CGRP-positive cells (but not IB4- of BF200-positive cells) in the
dorsal root ganglia (DRG) has been shown26 and this increase was
observed for up to 28 days27. There is also evidence that CGRP acts
on primary afferent neurons: DRGs express CGRP receptors and
these cells can be activated directly by CGRP (resulting in Caþþ
mobilization) and CGRP enhances tetrodotoxin-resistant Naþ cur-
rents in a proportion of DRGs28,29. Furthermore, a peripheral in-
ﬂuence on central neurons is also suggested by the up-regulation of
Fos in the trigeminal subnuclei caudalis in a tooth ache model in
ferret; interestingly, this effect was inhibited with a subcutaneously
administered CGRP-neutralizing antibody30. These ﬁndings suggest
that the neurogenic inﬂammation in the joint provides the pe-
ripheral drive for the induction of a phenotypic switch in primary
afferent neurons, leading to central sensitization. The very long
duration of effect we observed with LY2951742 in the MT model
would suggest that CGRP is involved in inducing and/or main-
taining this phenotypic switch and that neutralization of CGRP al-
lows for a reversal. This needs to be investigated in future studies.
NSAIDs are widely used to alleviate pain in patients with OA, but
their use is associated with increased gastrointestinal and cardio-
vascular risk31. Moreover, a large proportion of OA patients only
experience limited pain relief, and in others, NSAIDs are no longer
effective or are contra-indicated. Our current ﬁndings indicate that
neutralization of CGRP alleviates pain through a different, inde-
pendent mechanism from NSAIDs: we found additivity in the MIA
model where animals were still responsive to NSAIDs and CGRP
neutralization was still effective in animals that no longer respon-
ded to a high dose of diclofenac. The increase in CGRP-positive
ipsilateral DRG neurons in the rat MIA model26,27 has also been
reported (for up to 35 days) in the complete Freund’s adjuvant-
induced inﬂammation of the joint in rat32. This increase was
reduced by rofecoxib treatment, whereas paracetamol had no ef-
fect, thus establishing a link between the induction of prostaglan-
dins and CGRP32. In the same model, inhibition of the CGRP
receptor with BIBN4096BS resulted in decreased pain behavior,
similar to that observed with the NSAID ketorolac33. Interestingly,
the inhibition was only observed when BIBN4096BS was adminis-
tered peripherally (intravenously), and not in the spinal cord,
supporting our ﬁndings with the CGRP-neutralizing antibody,
which has very limited ability to penetrate into the spinal cord.
These authors did not report any NSAID/BIBN4096BS combination
treatments. Together, peripheral (joint) inﬂammation appears to
induce a prolonged increase in CGRP-positive DRG neurons, a
process likely involving prostaglandins, leading to chronic pain.
Neutralization of the CGRP pathway in these inﬂammatory pain
models results in pain relief. Our ﬁndings that CGRP neutralization
is effective independent of NSAIDs could provide an important
treatment option for many OA patients.
Capsaicin-induced vasodilatation monitored by LDI was used as
a biologically relevant response for target engagement to deter-
mine the effect of LY2951742 after a single injection in the rat. The
results clearly demonstrate that LY2951742 can effectively
neutralize CGRP in vivo for at least 5 days post dosing. A similar
method has been used by others to assess target engagement of
small molecule inhibitors at the CGRP receptor in the periphery in
both pre-clinical34 and clinical35 settings. In addition, a similar
assay studying ﬂare size has been used to assess molecules targeted
at inhibiting the TRPV1 channel36. These LDI-based assays have
R.J. Benschop et al. / Osteoarthritis and Cartilage 22 (2014) 578e585584provided target engagement evidence that allowed these inhibitors
to move forward in clinical testing and for dose assessment. The
reproducibility of the dermal capsaicin LDI blood ﬂow assay has
been shown in the clinic37. The utility of the application of the LDI
capsaicin blood ﬂow assay for testing antibodies either to CGRP or
the CGRP receptor in the clinic remains to be determined, but could
provide an interesting way to demonstrate CGRP neutralization in
man.
While the CGRP pathway has been validated in the clinic for
migraine with small molecule inhibitors, our data provide evidence
for the involvement of CGRP in OA-related pain andwarrant further
clinical investigations with LY2951742 in OA patients.
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